Logo image of EPRX.CA

EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Stock Fundamental Analysis

TSX:EPRX - Toronto Stock Exchange - CA29842P1053 - Common Stock - Currency: CAD

5.16  -0.11 (-2.09%)

Fundamental Rating

3

Overall EPRX gets a fundamental rating of 3 out of 10. We evaluated EPRX against 22 industry peers in the Biotechnology industry. While EPRX has a great health rating, there are worries on its profitability. EPRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EPRX has reported negative net income.
EPRX had a negative operating cash flow in the past year.
In the past 5 years EPRX always reported negative net income.
EPRX had a negative operating cash flow in each of the past 5 years.
EPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFEPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

EPRX has a Return On Assets of -72.98%. This is in the better half of the industry: EPRX outperforms 63.64% of its industry peers.
The Return On Equity of EPRX (-76.34%) is better than 81.82% of its industry peers.
Industry RankSector Rank
ROA -72.98%
ROE -76.34%
ROIC N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPRX.CA Yearly ROA, ROE, ROICEPRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

EPRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX.CA Yearly Profit, Operating, Gross MarginsEPRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

EPRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EPRX has been increased compared to 5 years ago.
EPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EPRX.CA Yearly Shares OutstandingEPRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EPRX.CA Yearly Total Debt VS Total AssetsEPRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

EPRX has an Altman-Z score of 45.49. This indicates that EPRX is financially healthy and has little risk of bankruptcy at the moment.
EPRX's Altman-Z score of 45.49 is amongst the best of the industry. EPRX outperforms 100.00% of its industry peers.
EPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 45.49
ROIC/WACCN/A
WACCN/A
EPRX.CA Yearly LT Debt VS Equity VS FCFEPRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

EPRX has a Current Ratio of 11.10. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
EPRX's Current ratio of 11.10 is amongst the best of the industry. EPRX outperforms 100.00% of its industry peers.
EPRX has a Quick Ratio of 11.10. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
EPRX has a better Quick ratio (11.10) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 11.1
Quick Ratio 11.1
EPRX.CA Yearly Current Assets VS Current LiabilitesEPRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

EPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.74%, which is quite good.
EPS 1Y (TTM)15.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

EPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.38%
EPS Next 2Y28.45%
EPS Next 3Y26.46%
EPS Next 5Y14.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX.CA Yearly Revenue VS EstimatesEPRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
EPRX.CA Yearly EPS VS EstimatesEPRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EPRX. In the last year negative earnings were reported.
Also next year EPRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX.CA Price Earnings VS Forward Price EarningsEPRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX.CA Per share dataEPRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as EPRX's earnings are expected to grow with 26.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.45%
EPS Next 3Y26.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EPRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUPRAXIA PHARMACEUTICALS INC

TSX:EPRX (5/22/2025, 7:00:00 PM)

5.16

-0.11 (-2.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08
Earnings (Next)N/A N/A
Inst Owners13.09%
Inst Owner ChangeN/A
Ins Owners22.83%
Ins Owner ChangeN/A
Market Cap184.99M
Analysts85
Price Target10.33 (100.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-33.53%
Min EPS beat(2)-80.04%
Max EPS beat(2)12.99%
EPS beat(4)3
Avg EPS beat(4)-11.7%
Min EPS beat(4)-80.04%
Max EPS beat(4)18.21%
EPS beat(8)6
Avg EPS beat(8)-4.91%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-40.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.99
P/tB 3.99
EV/EBITDA N/A
EPS(TTM)-1.43
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS1.29
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.98%
ROE -76.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.4%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.1
Quick Ratio 11.1
Altman-Z 45.49
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.53%
Cap/Depr(5y)142.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y5.38%
EPS Next 2Y28.45%
EPS Next 3Y26.46%
EPS Next 5Y14.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y47.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-44.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.56%
OCF growth 3YN/A
OCF growth 5YN/A